ibrutinib,venetoclax
abbvie,janssen,roche
['lymsm']
an interesting aspect of this sequence of events is that the median exposure to therapy was ~11 months - will be interesting to see durability of time-limited therapy &amp; sensitivity to btki at progression, in this context #lymsm #ash22 #wm
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer